ZIOP) ("Ziopharm"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZIOP as the Company's latest news hit the wire. On February 12, 2018, the Company, which is a biotechnology Company that works towards the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, shared pre-clinical data regarding its Sleeping Beauty technology at the ‘Emerging Cellular Therapies: T Cells and Beyond (B6)' conference in the Keystone Symposia. The Keystone Symposia is being held in Keystone, Colorado from February 11 to February 15, 2018, and brings together the scientific community working towards accelerating life science discovery. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ziopharm Oncology most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ZIOP

The data validated that point-of-care manufacturing of human T cells expressing chimeric antigen receptor (CAR) have an anti-tumor effect in pre-clinical models. The market responded well to this news, as Ziopharm shares were up 8% pre-market on light volume.

About Ziopharm's Sleeping Beauty System

Ziopharm is developing two platform technologies – Controlled IL-12 and Sleeping Beauty - for delivering safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. The Company is developing these technologies in partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corp. (NYSE: XON).

Sleeping Beauty is a non-viral approach for genetically modifying chimeric antigen receptor (CAR+) and T-cell receptor (TCR+) T cells, which target specific antigens in blood cancers and neo-antigens solid tumors. Ziopharm intends to initiate the first in-human trial for utilizing this approach in 2018.

Sleeping Beauty has been developed by leveraging Ziopharm's point-of-care technology, which is a shortened manufacturing process that has the potential to be established as a decentralized manufacturing process in hospitals. The Company believes that the point-of-care manufacturing process can bring down costs associated with T-cell therapies. Besides, it also avoids the need for centralized manufacturing, as is the case when using a virus to genetically modify T cells.

Data Based on Ziopharm's Recent Research

Lenka V. Hurton, Ph.D., a researcher in the Division of Pediatrics at the University of Texas MD Anderson Cancer Center, presented the findings in a talk entitled ‘Rapid production of T cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes in vivo memory'. She also made a poster presentation under the same title during the Keystone Symposia.

The content in Dr. Hurton's poster and presentation slides is based on the research conducted by Ziopharm in collaboration with the University of Texas MD Anderson Cancer Center and Precigen.

The presented data highlighted that T cells expressing CD19-specific CAR with membrane-bound IL-15 (mbIL15) were generated with the non-viral Sleeping Beauty system in less than two days. In fact, it did not even require ex vivo activation or propagation. The data also validated that T cells designed to express mbIL15 exhibited greater persistence and more potent antitumor activity than comparator T cells without mbIL15 in these studies.

Stock Performance Snapshot

February 13, 2018 - At Tuesday's closing bell, Ziopharm Oncology's stock marginally down 0.51%, ending the trading session at $3.92.

Volume traded for the day: 1.36 million shares.

After yesterday's close, Ziopharm Oncology's market cap was at $552.21 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 489214

"/> Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia « MarketersMedia – Press Release Distribution Services – News Release Distribution Services
How It Works? Plans & Pricing Our Distributions Newsroom Info Hub Sign Up Sign In Send Press Release Contact Sales
Contact Sales Sign Up Your Account Send Press Release
MarketersMEDIA / Newsroom / Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia

Wired News – Ziopharm Oncology Presents Data on Rapid Production of CAR T Cells at Keystone Symposia

Share This Press Release

LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZIOP as the Company's latest news hit the wire. On February 12, 2018, the Company, which is a biotechnology Company that works towards the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, shared pre-clinical data regarding its Sleeping Beauty technology at the ‘Emerging Cellular Therapies: T Cells and Beyond (B6)' conference in the Keystone Symposia. The Keystone Symposia is being held in Keystone, Colorado from February 11 to February 15, 2018, and brings together the scientific community working towards accelerating life science discovery. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ziopharm Oncology most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ZIOP

The data validated that point-of-care manufacturing of human T cells expressing chimeric antigen receptor (CAR) have an anti-tumor effect in pre-clinical models. The market responded well to this news, as Ziopharm shares were up 8% pre-market on light volume.

About Ziopharm's Sleeping Beauty System

Ziopharm is developing two platform technologies – Controlled IL-12 and Sleeping Beauty - for delivering safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. The Company is developing these technologies in partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corp. (NYSE: XON).

Sleeping Beauty is a non-viral approach for genetically modifying chimeric antigen receptor (CAR+) and T-cell receptor (TCR+) T cells, which target specific antigens in blood cancers and neo-antigens solid tumors. Ziopharm intends to initiate the first in-human trial for utilizing this approach in 2018.

Sleeping Beauty has been developed by leveraging Ziopharm's point-of-care technology, which is a shortened manufacturing process that has the potential to be established as a decentralized manufacturing process in hospitals. The Company believes that the point-of-care manufacturing process can bring down costs associated with T-cell therapies. Besides, it also avoids the need for centralized manufacturing, as is the case when using a virus to genetically modify T cells.

Data Based on Ziopharm's Recent Research

Lenka V. Hurton, Ph.D., a researcher in the Division of Pediatrics at the University of Texas MD Anderson Cancer Center, presented the findings in a talk entitled ‘Rapid production of T cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes in vivo memory'. She also made a poster presentation under the same title during the Keystone Symposia.

The content in Dr. Hurton's poster and presentation slides is based on the research conducted by Ziopharm in collaboration with the University of Texas MD Anderson Cancer Center and Precigen.

The presented data highlighted that T cells expressing CD19-specific CAR with membrane-bound IL-15 (mbIL15) were generated with the non-viral Sleeping Beauty system in less than two days. In fact, it did not even require ex vivo activation or propagation. The data also validated that T cells designed to express mbIL15 exhibited greater persistence and more potent antitumor activity than comparator T cells without mbIL15 in these studies.

Stock Performance Snapshot

February 13, 2018 - At Tuesday's closing bell, Ziopharm Oncology's stock marginally down 0.51%, ending the trading session at $3.92.

Volume traded for the day: 1.36 million shares.

After yesterday's close, Ziopharm Oncology's market cap was at $552.21 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 489214

LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on Ziopharm Oncology, Inc. (NASDAQ: ZIOP) ("Ziopharm"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZIOP as the Company's latest news hit the wire. On February 12, 2018, the Company, which is a biotechnology Company that works towards the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer, shared pre-clinical data regarding its Sleeping Beauty technology at the ‘Emerging Cellular Therapies: T Cells and Beyond (B6)' conference in the Keystone Symposia. The Keystone Symposia is being held in Keystone, Colorado from February 11 to February 15, 2018, and brings together the scientific community working towards accelerating life science discovery. Register today and get access to over 1000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Ziopharm Oncology most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=ZIOP

The data validated that point-of-care manufacturing of human T cells expressing chimeric antigen receptor (CAR) have an anti-tumor effect in pre-clinical models. The market responded well to this news, as Ziopharm shares were up 8% pre-market on light volume.

About Ziopharm's Sleeping Beauty System

Ziopharm is developing two platform technologies – Controlled IL-12 and Sleeping Beauty - for delivering safe, effective, and scalable cell- and viral-based therapies for the treatment of multiple cancer types. The Company is developing these technologies in partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corp. (NYSE: XON).

Sleeping Beauty is a non-viral approach for genetically modifying chimeric antigen receptor (CAR+) and T-cell receptor (TCR+) T cells, which target specific antigens in blood cancers and neo-antigens solid tumors. Ziopharm intends to initiate the first in-human trial for utilizing this approach in 2018.

Sleeping Beauty has been developed by leveraging Ziopharm's point-of-care technology, which is a shortened manufacturing process that has the potential to be established as a decentralized manufacturing process in hospitals. The Company believes that the point-of-care manufacturing process can bring down costs associated with T-cell therapies. Besides, it also avoids the need for centralized manufacturing, as is the case when using a virus to genetically modify T cells.

Data Based on Ziopharm's Recent Research

Lenka V. Hurton, Ph.D., a researcher in the Division of Pediatrics at the University of Texas MD Anderson Cancer Center, presented the findings in a talk entitled ‘Rapid production of T cells co-expressing CAR and membrane-bound IL-15 potentiates antitumor activity and promotes in vivo memory'. She also made a poster presentation under the same title during the Keystone Symposia.

The content in Dr. Hurton's poster and presentation slides is based on the research conducted by Ziopharm in collaboration with the University of Texas MD Anderson Cancer Center and Precigen.

The presented data highlighted that T cells expressing CD19-specific CAR with membrane-bound IL-15 (mbIL15) were generated with the non-viral Sleeping Beauty system in less than two days. In fact, it did not even require ex vivo activation or propagation. The data also validated that T cells designed to express mbIL15 exhibited greater persistence and more potent antitumor activity than comparator T cells without mbIL15 in these studies.

Stock Performance Snapshot

February 13, 2018 - At Tuesday's closing bell, Ziopharm Oncology's stock marginally down 0.51%, ending the trading session at $3.92.

Volume traded for the day: 1.36 million shares.

After yesterday's close, Ziopharm Oncology's market cap was at $552.21 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 489214

Source URL: https://marketersmedia.com/wired-news-ziopharm-oncology-presents-data-on-rapid-production-of-car-t-cells-at-keystone-symposia/300935

Source: AccessWire

Release ID: 300935

Latest Releases

Our Client

Subscribe and Recieve exclusive insider tips and tricks on Press Release.

Follow Us

Copyright © 2012 - 2018 MarketersMedia – Press Release Distribution Services – News Release Distribution Services. All Rights Reserved.

Powered by Semantics BigData Analytics (SBDA).